Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
MediMabBio logo — A biotechnology company that focuses on developing new thera...

MediMabBio

A biotechnology company that focuses on developing new therapeutic drugs targeting Oncology and Inflammatory Disease

Founded 2017 Korea South Korea South 15 employees Non Equity Assistance Biotechnology, Health Care +1

General Information

Company Name MediMabBio
Founded Year 2017
Location Korea South Korea South
Employees 15
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Non Equity Assistance
Social

BounceWatch is an independent company data service, not affiliated with MediMabBio. To contact MediMabBio, visit medimabbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MediMabBio compare?

A PDF of MediMabBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MediMabBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MediMabBio

MediMabBio is a biotechnology company founded in 2017, with its headquarters in Korea South. The company's slogan emphasizes its focus on developing new therapeutic drugs targeting Oncology and Inflammatory Disease. MediMabBio is dedicated to the generation of novel immunotherapies for the treatment of cancer using advances in systems biology and immunological solutions. The company has developed a pipeline of highly promising drugs and has established collaborations with academic, R&D institutions, and clinical groups in US, UK, Germany, China, and Korea.

The last investment received by MediMabBio was in the form of non-equity assistance at 01 May 2017. The investors in this round were Sunbo Partners and the TIPS Program.

MediMabBio's innovative approach and strategic partnerships position it well in the Biotechnology, Health Care, and Pharmaceutical industries, promising significant advancements in the development of immuno-oncology drugs to address the current limitations of cancer immunotherapy.

Business keywords: therapeutic drugs, oncology, inflammatory disease, immunotherapy, cancer treatment, systems biology, immunological solutions, novel drugs, immuno-oncology, antibody discovery, R&D collaborations, academic partnerships, solid tumors, drug development

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance Undisclosed 2
Sunbo Partners
Sunbo Partners, TIPS Program
01 May 2017

MediMabBio Alternatives & Competitors

View All Alternatives
MediMabBio vs
Surface Oncology Inc.
Surface Oncology Inc. United States

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021

Post-IPO Equity
14 employees
Biotechnology, Health Care
MediMabBio vs
DEM Biopharma, Inc.
DEM Biopharma, Inc. United States

Novel Target for Solid Tumors

20 employees
Biotechnology, Life Sciences
MediMabBio vs
Imugene Limited
Imugene Limited Australia

Bringing Effective New Treatments And Options To Patients Who Need Them

IPO
26 employees
Biotechnology, Health Care
View all alternatives

FAQ About MediMabBio

A biotechnology company that focuses on developing new therapeutic drugs targeting Oncology and Inflammatory Disease
MediMabBio was founded in 2017.
MediMabBio is headquartered in Korea South.
MediMabBio operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on therapeutic drugs, oncology, inflammatory disease and immunotherapy.
MediMabBio has approximately 15 employees.
MediMabBio has completed 1 funding round. The latest funding stage is Non Equity Assistance.
Top alternatives and competitors to MediMabBio include Surface Oncology Inc., DEM Biopharma, Inc., Imugene Limited, OSE Immunotherapeutics, AltruBio Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MediMabBio and Surface Oncology Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MediMabBio, https://bouncewatch.com/company/medimabbio, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout